Safety and Immunological Effect of Pembrolizumab in Resectable or Borderline Resectable Pancreatic Cancer
NCT02305186
·
clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
UNKNOWN
Status
68
Enrollment
OTHER
Sponsor class
Conditions
Pancreatic Cancer
Interventions
DRUG:
Pembrolizumab
RADIATION:
Neoadjuvant Chemoradiation
Sponsor
Craig L Slingluff, Jr